This is a phase 3, adaptive, multicenter, randomized, double-blind, placebo control study to evaluate the safety, immunogenicity, and efficacy of the Nanocovax vaccine against COVID-19 in volunteer subjects 18 years of age and older.
Age stratified as 18-45, 45-60, and \> 60 years of age.
The assessment of immunogenicity will be further expanded in a subset of Phase 3 (1000 participants).
Randomly assigned to vaccine or placebo group with a ratio of 2:1 (2 subjects injected with Nanocovax 25 mcg : 1 subject injected with placebo).
